This study investigates AVA6103 in patients with locally advanced or metastatic solid tumors. AVA6103 is being studied to understand its effects on these types of tumors which are likely to be FAP positive.
The study evaluates the safety and tolerability of AVA6103. Researchers will look at how patients respond to the investigational medication to determine the best dose for further studies.
- Who can participate: Adults 18 years and older with certain FAP positive tumors like cervical/vulvar cancer, SCLC, gastric/GEJ cancer, and PDAC may participate. Participants must have tried all standard treatments or be ineligible for them.
- Study details: Participants will receive AVA6103 intravenously. Some may receive an inactive substance called a placebo, which looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand